Belt and Road Summit 2025- Deal-making

10–16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 4 September 2025

Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)

Haiyang Wang

CEO at Shanghai Haiju Biotechnology Co., Ltd.

Shanghai, China

About

HJ-462 features protein kinase inhibitors with ingenious molecular designs that avoid defects in drug metabolism within the body, resulting in excellent safety and remarkable efficacy(achieving 100% tumor regression in liver cancer, gastric cancer, and lung cancer models caused by MET amplification, effectively curing these conditions).

Project Location

  • China

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Feasibility Study Completed

Main Project Sector

  • Technology

Technology

  • Bio-Tech

Interested Format of Cooperation

  • Joint Venture
  • Minority Shareholdings
  • Open for Negotiation
  • R&D Cooperation

Preferred Financing Model

  • Equity
  • Open for negotiation

Previous Funding Stage

  • Seed & Pre-Series

Main Service(s) Required

  • Financial Services
  • Professional Services

Financial Services

  • Institutional Investment
  • Private Equity & Venture Capital

Professional Services

  • Business Valuation
  • Corporate Services
  • Market Entry Strategic Analysis

Organisation

Similar opportunities

  • Project

    Novel Platinum-Based Drug Targeting Tumor Microenvironment (HJ-550 )

    • Yes
    • Equity
    • Bio-Tech
    • Technology
    • Joint Venture
    • Legal Advisory
    • Private Project
    • R&D Cooperation
    • Seed & Pre-Series
    • Financial Services
    • Investment Banking
    • Business Valuation
    • Corporate Services
    • Open for Negotiation
    • Professional Services
    • Minority Shareholdings
    • Feasibility Study Completed
    • Private Equity & Venture Capital

    Haiyang Wang

    CEO at Shanghai Haiju Biotechnology Co., Ltd.

    Shanghai, China

  • Project

    Liver-in-Cube

    • No
    • Bio-Tech
    • Operations
    • Technology
    • IP Related
    • Consultancy
    • R&D Cooperation
    • Risk Management
    • Health Technology
    • Seed & Pre-Series
    • Medical Technology
    • Financial Services
    • Business Valuation
    • Financial Advisory
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 5,000,001 to 7,500,000 USD
    • 10,000,001 to 25,000,000 USD
    • Private Equity & Venture Capital
    • Public-Private Partnership Project
    • Risk Management (Financial Services)

    Jiang Liu

    Research Assistant Professor at Oncoimmunostics Limited

    Hong Kong, China (Hong Kong)

  • Project

    Single Cell Drug Screening AI Platform

    • Yes
    • None
    • Equity
    • Bio-Tech
    • Technology
    • Private Project
    • R&D Cooperation
    • Open for negotiation
    • Professional Services
    • Minority Shareholdings
    • 2,500,001 to 5,000,000 USD
    • 1,000,001 to 2,500,000 USD
    • Feasibility Study Completed
    • Public–private partnership / Concession

    Marco Suen

    Founder & CEO at Provectus Therapeutics Limited

    Hong Kong, China (Hong Kong)